Cramer's 'Mad Money' Recap: Next Week's Game Plan

Tickers in this article: ABBV ABT ANF AZO BAX BBY BSX CPB CRM CSOD DLTR FB FL HD HEK HPQ JNJ LOW NTAP POT RDN ROST SHLD TGT TJX TOL UBNT WSM
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- As long as earnings continue to exceed expectations, this market won't see a meaningful pullback, Jim Cramer told his "Mad Money" TV show viewers Friday as he laid out his game plan for next week's trading.

Cramer said Monday he'll be watching Campbell's Soup , which is now overvalued against its historical average. He said investors need to pay attention to this stock as a bellwether for the rest of its sector, and he's not betting on a strong quarter or a strong reaction. Cramer said he's also looking for the IPOs of Ply Gem and ChannelAdvisor, both worth the investment.

Tuesday brings a host of retailers, including Best Buy , Home Depot , TJX Stores and AutoZone , along with NetApp . Cramer said he'd hold off on all of these names as retail has gotten too hot to handle and Net App is involved with an activist shareholder.

Wednesday brings Hewlett-Packard , Lowe's , Target and home builder Toll Brothers . Cramer said he's not betting on any of these stocks either, but would consider Lowe's if it sells off on Home Depot's quarter.

Then, on Thursday, Dollar Tree , Ross Stores , Sears Holdings and Williams-Sonoma , and also Salesforce.com . Cramer said he's expecting Salesforce to "shoot the lights out" and would only consider Sears and Williams-Sonoma on weakness.

Finally, on Friday, Foot Locker and Abercrombie & Fitch will report. Cramer said once again that expectations have gotten too high.

Speculation Friday

For "Speculation Friday," Cramer turned his sights on a stock that's been in decline for a full eight years, falling from $45 in 2005 to a mere $5 a share at the beginning of the year. That stock, Boston Scientific , has been riddled with problems, said Cramer, including slowing businesses, recalls and lawsuits and even Food and Drug Administration warning letters regarding quality control.

But since the beginning of the year, Boston Scientific has rallied 59% off its lows, from $5 a share to just over $9 today. Cramer said the combination of stabilization of its old products, along with the prospects of some exciting new ones, may have finally turned the tide for the company.